证券代码：600200 证券简称：*ST 苏吴 公告编号：临 2025-077 江苏吴中医药发展股份有限公司关于公司股票 可能被实施重大违法强制退市的第三次风险提示公告 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 截至本公告披露日，公司尚未收到就上述立案调查事项的正式处罚决定，公 司将全力配合中国证监会的相关工作,并严格按照相关要求履行信息披露义务。 如根据正式的行政处罚决定书结论，公司触及重大违法强制退市情形，公司股票 将被终止上市。 二、其他说明及风险提示 正式处罚决定为准。敬请广大投资者关注后续公告并注意投资风险。 司后续收到行政处罚决定书，显示公司触及重大违法类强制退市情形，公司将申 请停牌，并及时披露有关内容。上海证券交易所将在停牌之日起的 5 个交易日内， 向公司发出拟终止股票上市的事先告知书，后续将根据《上海证券交易所股票上 市规则》的相关规定，作出是否终止公司股票上市的决定。 公司指定信息披露媒体为《中国证券报》《上海证券报》以及上海证券交易 所网站（www.sse.com.cn），有关公司的信息均以上述指定媒体刊登的信息为准。 敬请投资者注意投资风险。 述或者重大遗漏， ...

Performance Disclosure - Tongzhou Electronics reported a revenue of 540 million yuan for the first half of 2025, an increase of 606.52% year-on-year, with a net profit attributable to shareholders of 203 million yuan, up 662.77% year-on-year, and a net profit of 208 million yuan after deducting non-recurring items, an increase of 588.4% year-on-year [1] - Zhejiang Dingli achieved a revenue of 4.336 billion yuan in the first half of 2025, a year-on-year growth of 12.35%, with a net profit attributable to shareholders of 1.051 billion yuan, up 27.49% year-on-year [2] - Rebecca reported a revenue of 598 million yuan for the first half of 2025, a year-on-year increase of 4.2%, with a net profit attributable to shareholders of 9.3759 million yuan, up 15.31% year-on-year, and basic earnings per share of 0.01 yuan [3] Shareholding Changes - Huashu High-Tech announced that its major shareholder, Guotou Technology Achievement Transformation Venture Capital Fund, reduced its shareholding from 7.00% to 5.93%, with a total of approximately 4.4437 million shares sold between July 1 and July 25, 2025 [4] - Zijin Mining's vice president plans to reduce his holdings by no more than 250,300 shares to raise funds for the company's 2025 employee stock ownership plan, with the reduction to occur within three months after the announcement date [5] - New Media Co. announced that its shareholder, Hengqin Hongtu Rongyao Venture Capital Partnership, plans to reduce its holdings by no more than 6.8434 million shares, representing up to 2.99% of the company's total share capital, through centralized bidding or block trading from August 18 to November 17, 2025 [6] Risk Matters - *ST Suwu announced that its stock may face mandatory delisting due to suspected violations of information disclosure, as the China Securities Regulatory Commission has initiated an investigation, identifying false records in its financial reports from 2020 to 2023 [7] - Beihua Co. confirmed that it has no undisclosed significant matters, despite its stock experiencing a cumulative price drop of over 20% in three consecutive trading days, indicating normal operational conditions [8] - Nanmin Group also stated that it has no undisclosed significant matters, following a similar price drop scenario, confirming that its operational conditions remain stable [9][10]

Core Viewpoint - The article highlights the increasing trend of strict regulatory measures against listed companies involved in serious violations, leading to forced delisting and criminal penalties for key offenders [2][10][12]. Group 1: Forced Delisting - On July 25, Jinzhou Port will be delisted due to serious violations, marking it as another company facing forced delisting [2]. - Since early 2025, nine companies have entered the delisting process due to serious violations, including Zhuolang Technology and Puli Pharmaceutical [11]. - The regulatory focus on serious violations for forced delisting has intensified, with the new policies established in April 2024 and July 2025 reinforcing this trend [10][11]. Group 2: Criminal Penalties - The regulatory environment has shifted towards a "three penalties linkage" approach, combining administrative, civil, and criminal penalties for serious violators [5][8]. - Companies like Jintongling and Ruiskanda have faced criminal charges after administrative and civil penalties, indicating a clear escalation in regulatory actions [6][8]. - The number of companies facing criminal penalties has increased significantly, with over ten companies experiencing criminal measures since early 2025 [7][8]. Group 3: Accountability of Third Parties - The regulatory body has begun to impose penalties on third parties involved in financial fraud, as seen in the Yuebo Power case where accomplices were fined [3][15]. - The trend of holding third parties accountable reflects a broader strategy to dismantle the networks that facilitate financial fraud in the capital market [15]. Group 4: Investor Protection - Regulatory measures are being enhanced to protect investors affected by fraudulent activities, including civil compensation initiatives [16]. - The introduction of advance compensation and commitments from administrative enforcement parties aims to provide timely restitution to investors [16].

Core Viewpoint - Fujian Zitian Media Technology Co., Ltd. (*ST Zitian*) is facing delisting due to significant financial misreporting, with the Shenzhen Stock Exchange planning to terminate its stock trading by July 23, 2025 [1][3]. Group 1: Financial Misconduct - The company has been found to have false records in its financial reports for 2022 and 2023, with a total misreported revenue of approximately 2.5 billion yuan, accounting for 63.53% of the total reported revenue for those years [3]. - The company received an administrative penalty notice from the Fujian Securities Regulatory Bureau, indicating that it violated the Shenzhen Stock Exchange's listing rules due to continuous false reporting of revenue exceeding 500 million yuan over two years [3]. Group 2: Company History and Transformation - Originally established as Nantong Forging Equipment Co., Ltd. in March 2002, the company was a leading manufacturer of hydraulic machines before its transition to the media sector [4]. - After going public in December 2011, the company faced declining sales and significant losses, with a net profit drop of 59.35% in its second year of listing [4]. - The company shifted its focus to acquisitions for business transformation, acquiring multiple companies in the advertising sector from 2017 to 2020, ultimately divesting its original forging equipment business [5][6]. Group 3: Recent Developments - In June 2022, the company announced plans to acquire 100% of Pea Pod, a leading digital service company, for 1.4 billion yuan, with a premium rate of 835.93%, but the deal was ultimately unsuccessful due to unfavorable market conditions [6].

Core Viewpoint - The company *ST Zitian (300280.SZ) is facing delisting due to significant financial misreporting, with a total of 2,499,275,347.89 yuan in false revenue reported for 2022 and 2023, accounting for 63.53% of the total disclosed revenue for those years [3]. Group 1: Company Background and History - *ST Zitian, originally known as Nantong Forging Equipment Co., Ltd., was established in March 2002 and was once a leading manufacturer of hydraulic machines in China [5]. - The company went public on the ChiNext board in December 2011 but faced declining sales and profitability due to economic downturns and industry overcapacity, resulting in a 59.35% year-on-year decline in net profit in its second year of listing [6]. Group 2: Business Transformation and Acquisitions - In response to declining performance, the company pursued a strategy of acquisitions to transform its business, acquiring 100% of Shenzhen Olive Leaf Technology in 2017 and 70% of Yijia Jingshi in 2018, among others [7]. - By 2021, the company had completely divested its forging equipment business and rebranded as Zitian Technology, focusing solely on modern advertising services, including internet advertising and cloud services [7][8]. Group 3: Financial Misconduct and Consequences - The company received an administrative penalty notice from the Fujian Securities Regulatory Bureau due to false financial reporting for two consecutive years, which could lead to mandatory delisting under the Shenzhen Stock Exchange rules [3]. - As of July 19, 2025, the company had not disclosed corrected financial reports, prompting the Shenzhen Stock Exchange to issue a notice of intent to terminate its stock listing [3].

Core Viewpoint - Jiangsu Wuzhong is facing a significant setback due to the unilateral termination of its exclusive agency rights for the AestheFill product by Regen Biotech, which the company claims is an act of "malicious breach of contract" by its partner Aimeike [2][8]. Group 1: Agency Dispute - Jiangsu Wuzhong's subsidiary, Datuo Medical, received a termination notice from Regen Biotech regarding the exclusive distribution agreement for AestheFill [2][4]. - Regen Biotech alleges that Datuo Medical violated the agreement by transferring the agency rights to its parent company, Jiangsu Wuzhong Meisheng Biotechnology [4]. - The termination has led to Regen Biotech refunding payments for undelivered orders, further complicating Jiangsu Wuzhong's financial situation [2]. Group 2: Financial Impact - AestheFill, known as the "童颜针" (youthful needle), was a key product for Jiangsu Wuzhong, contributing significantly to its revenue and profit [13]. - In 2024, Jiangsu Wuzhong reported a revenue of 1.599 billion, with AestheFill sales accounting for 326 million, representing 20.42% of total revenue [13]. - The loss of exclusive agency rights could drastically reduce Jiangsu Wuzhong's income and profit, as AestheFill was a major driver of its financial recovery [13]. Group 3: Company Performance and Challenges - Jiangsu Wuzhong has struggled with poor financial performance, reporting losses in multiple years since 2018 [11]. - The company is also facing potential delisting due to significant financial irregularities, including inflated revenues and profits from 2020 to 2023 [14]. - The stock price of Jiangsu Wuzhong has declined by 4.71%, closing at 1.62 yuan, reflecting investor concerns over its financial stability [14].

Core Viewpoint - *ST Zitian may face delisting due to failure to rectify financial reporting issues and has been suspended from trading starting July 21, 2025 [2][4]. Summary by Sections Financial Reporting Issues - On February 14, *ST Zitian received a notice from the Fujian Securities Regulatory Bureau requiring corrections to its financial reports due to false records [4]. - The company failed to complete the required corrections within the stipulated 30 days, leading to a trading suspension starting March 17 [4]. - As of July 20, *ST Zitian had not engaged a qualified accounting firm or submitted a rectification report, triggering potential delisting under Shenzhen Stock Exchange rules [4]. Regulatory Actions - The company has faced multiple regulatory actions, including a notice of investigation from the China Securities Regulatory Commission (CSRC) for failing to disclose periodic reports on time [6]. - On June 27, *ST Zitian received a prior notice of administrative penalty, with identified false records in its 2022 and 2023 annual reports amounting to CNY 2.499 billion, representing 63.53% of the reported revenue for those years [6][7]. Financial Performance - The company reported a significant decline in net profit for 2023, with a net profit of CNY 0.08 million, down 95.97% year-on-year [9]. - Total revenue for the first three quarters of 2024 was CNY 11.80 million, a decrease of 48.45% compared to the previous year [9]. - The total cost of operations also decreased to CNY 11.69 million, reflecting a similar downward trend in financial performance [9]. Market Position - As of July 18, *ST Zitian's stock price was CNY 2.74 per share, with a total market capitalization of CNY 440 million [10].

Core Viewpoint - Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. faces the risk of being forcibly delisted due to major legal violations, as the China Securities Regulatory Commission (CSRC) has initiated an investigation into the company for suspected information disclosure violations [1][3]. Group 1: Investigation and Legal Proceedings - The company received a notice from the CSRC on February 26, 2025, indicating that it is under investigation for engaging in trade activities with related companies that lacked commercial substance, resulting in inflated revenue, costs, and profits from 2020 to 2023 [1][3]. - The inflated figures include a revenue increase of 26.46%, 26.39%, 21.26%, and 16.82% for the years 2020 to 2023, respectively, along with inflated costs amounting to 480.68 million, 448.24 million, 410.82 million, and 355.44 million yuan, which represented 37.08%, 35.47%, 28.40%, and 20.95% of the reported costs for the same periods [1][3]. Group 2: Potential Consequences - If the formal administrative penalty decision indicates that the company has committed major legal violations, its stock will be terminated from listing [2][3]. - The company will apply for a trading suspension upon receiving the administrative penalty decision and will disclose relevant information promptly [2][3]. Group 3: Compliance and Communication - The company commits to fully cooperating with the CSRC and will exercise its rights to defend itself during the investigation process [3]. - Investors are advised to pay attention to subsequent announcements regarding the investigation and potential risks associated with their investments [2][3].

Core Viewpoint - The company Tuisijingang is set to be delisted from the stock exchange due to serious financial misconduct, including falsifying financial reports and inflating profits over several years [5][6][7]. Group 1: Delisting Announcement - Tuisijingang's stock will be suspended from trading on July 21, 2025, with the last trading day being July 18, 2025, and the delisting date set for July 25, 2025 [1][6]. - After delisting, the company's shares will transition to the National Equities Exchange and Quotations (NEEQ) system for trading [7]. Group 2: Financial Misconduct - The company has been involved in financial fraud, with inflated profits reported for the years 2022 to 2024, including a profit inflation of 36.10 million yuan in 2022 (22.46% of reported profit), 68.08 million yuan in 2023 (65.96%), and 15.38 million yuan in Q1 2024 (62.05%) [5]. - The China Securities Regulatory Commission (CSRC) has imposed a fine of 20 million yuan on Tuisijingang and issued warnings to 11 responsible individuals, including a 10-year market ban for the former Deputy General Manager and CFO [5][6]. Group 3: Company Background - Tuisijingang primarily engages in logistics services for bulk commodities, including oil, chemicals, grains, coal, metals, and steel [5]. - The company was listed on the B-share market in May 1998 and on the A-share market in June 1999 [5].

Core Viewpoint - *ST Guandao has experienced a significant stock price increase of over 250%, leading to a suspension for investigation due to abnormal trading activities [2][6][8]. Group 1: Stock Performance and Suspension - *ST Guandao's stock price rose by 251.49% from June 25, 2025, to July 16, 2025, significantly deviating from the North Securities 50 Index, which increased by 251.64% during the same period [6]. - The company announced a stock suspension starting July 17, 2025, expected to last no more than five trading days, to investigate the recent price volatility [4][8]. Group 2: Regulatory Actions - Two personal accounts involved in the speculative trading of *ST Guandao have been subjected to regulatory measures, including a one-month trading restriction from July 16 to August 15, 2025 [10][13]. - The North Exchange has highlighted abnormal trading behaviors, including maintaining price limits and manipulating stock prices, which could mislead other investors [10][13]. Group 3: Legal and Compliance Issues - *ST Guandao is under investigation by the China Securities Regulatory Commission (CSRC) for significant internal control issues, with potential consequences including mandatory delisting due to major violations [17]. - The company has been found to have fabricated sales and procurement documents to inflate revenue and costs, leading to false disclosures in multiple financial reports from 2018 to 2024 [17]. - The controlling shareholder, Jin Wenming, is implicated in allowing and coordinating financial fraud, facing penalties including a warning and a fine of 15 million yuan [17]. Group 4: Company Overview - *ST Guandao specializes in the research, development, and sales of data collection and analysis software products [18].